美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

信息服務

5.19

+0.12002.37%

成交量：15.99萬

成交額：82.86萬

市值：2.51億

市盈率：21.64

高：5.21

開：5.12

低：5.09

收：5.07

52周最高：6.45

52周最低：3.74

股本：4,841.35萬

流通股本：3,555.23萬

量比：0.94

換手率：0.45%

股息：0.18

股息率：3.47%

每股收益(TTM):0.2399

每股收益(LYR):0.1900

淨資產收益率：12.30%

總資產收益率：6.36%

市淨率：2.62

市盈率(LYR):27.32

資料載入中...

總覽公司新聞公告

藥捷安康-B(02617)：替恩戈替尼單藥治療晚期膽管癌患者確證性III期臨床完成首例患者給藥

來凱LAE002乳腺癌III期臨床達到主要終點

中國生物製藥(01177)：維特柯妥拜單抗「CLDN18.2 ADC」一線胃及胃食管交界部腺癌III期臨床試驗完成首例患者入組

來凱醫藥-B(02105)：LAE 002(Afuresertib)III期臨床試驗(AFFIRM-205)達到無進展生存期(PFS)的主要終點

軒竹生物-B(02575)：安奈拉唑鈉新適應症獲批開展III期臨床試驗

港股異動 | 再鼎醫藥(09688)升逾3% 近日與安進達成全球臨床合作 Zoci正處於全球註冊性臨床III期階段

港股異動 | 科笛-B(02487)升逾3% CU-20101（注射用A型肉毒毒素）完成中國III期臨床試驗

做好信息服務破解人崗錯配

科笛-B(02487)：CU-20101(注射用A型肉毒毒素)用於改善中度至重度眉間紋完成中國III期臨床試驗

深桑達Ａ：公司研發重點圍繞數字與信息服務業務中的「雲數智」相關產品

開山股份(300257.SZ)肯尼亞Menengai III 35兆瓦地熱電站投入商業運營

眾議院民主黨人要求緊急投票以阻止「第三次世界大戰」

美國對失蹤飛行員信息泄露事件展開調查

西藏自治區互聯網新聞信息服務單位許可信息

中国西藏新闻网

百利天恒：iza-bren聯合用藥獲2個II/III期臨床試驗批准

每日经济新闻

港股異動 | 歐康維視生物-B(01477)午後升逾16% OT-211治療乾眼症III期臨床試驗完成首例患者入組

康寧傑瑞製藥-B(09966)：KN026新輔助治療HER2陽性乳腺癌III期臨床研究達到主要終點

宜明昂科-B(01541)：IMM0306治療複發性╱難治性濾泡性淋巴瘤的III期臨床試驗完成首例患者給藥

歐康維視生物-B(01477)：OT-211 III期臨床試驗完成首例患者入組

益方生物(688382.SH)：D-2570治療銀屑病註冊性III期臨床試驗完成全部受試者入組

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/III/news?page=8"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"III","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"III\",,,,,undefined,":{"symbol":"III","market":"US","secType":"STK","nameCN":"信息服務","latestPrice":5.19,"timestamp":1789156800000,"preClose":5.07,"halted":0,"volume":159870,"delay":0,"changeRate":0.023668639053254458,"floatShares":35552300,"shares":48413462,"eps":0.239856,"marketStatus":"盤前交易","change":0.12,"latestTime":"09-14 05:55:00 EDT","open":5.12,"high":5.2055,"low":5.09,"amount":828609.6472049999,"amplitude":0.022781,"askPrice":5.65,"askSize":407,"bidPrice":3.78,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.239856,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789392600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1171256400000,"exchange":"NASDAQ","adjPreClose":5.19,"dividendRate":0.034682,"postHourTrading":{"tag":"盘后","latestPrice":5.1942,"preClose":5.19,"latestTime":"18:01 EDT","volume":6848,"amount":35538.93,"timestamp":1789164063186,"change":0.0042,"changeRate":0.000809,"amplitude":0.000809},"volumeRatio":0.9375505815927984,"impliedVol":1.2381,"impliedVolPercentile":0.524},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"III\",,,,,undefined,":{"symbol":"III","floatShares":35552300,"roa":"6.36%","roe":"12.30%","lyrEps":0.19,"volumeRatio":0.9375505815927984,"shares":48413462,"dividePrice":0.18,"high":5.2055,"amplitude":0.022781,"preClose":5.07,"low":5.09,"week52Low":3.74,"pbRate":"2.62","psRate":"1.00","week52High":6.4495,"institutionHeld":0.6836,"latestPrice":5.19,"committee":-0.605523,"eps":0.239856,"divideRate":0.034682,"volume":159870,"delay":0,"ttmEps":0.239856,"open":5.12,"prevYearClose":5.78,"prevWeekClose":5.19,"prevMonthClose":5.12,"prevQuarterClose":4.11,"fiveDayClose":5.13,"twentyDayClose":5.17,"sixtyDayClose":4.12,"dividendPayoutRate":0.9280598907982862,"dividendFrequency":"Q","dividendGrowthYears":4,"dividendGrowthRate":0,"fiveYearAvgDividendRate":0.03333720106347336},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/III\",params:#limit:5,,,undefined,":[{"date":"2026-09-04","symbol":"III","amount":0.045,"announcedDate":"2026-08-05","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-04","defaultRemindTime":1788528600000,"name":"信息服务","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-25","payableDate":"2026-09-04","currency":"USD","dateTimestamp":1788494400000,"payDate":"2026-09-25"},{"market":"US","date":"2026-08-05","symbol":"III","fiscalQuarterEnding":"2026/06","expectedEps":0.06,"name":null,"time":"盤後","type":"earning","dateTimestamp":1785902400000,"reportTimeType":"post","actualEps":0.07},{"date":"2026-06-05","symbol":"III","amount":0.045,"announcedDate":"2026-05-07","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-05","defaultRemindTime":1780666200000,"name":"信息服务","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-05","currency":"USD","dateTimestamp":1780632000000,"payDate":"2026-06-26"},{"market":"US","date":"2026-05-07","symbol":"III","fiscalQuarterEnding":"2026/03","expectedEps":0.05,"name":null,"time":"盤後","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"post","actualEps":0.06},{"date":"2026-03-20","symbol":"III","amount":0.045,"announcedDate":"2026-03-05","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-20","defaultRemindTime":1774013400000,"name":"信息服务","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-26","payableDate":"2026-03-20","currency":"USD","dateTimestamp":1773979200000,"payDate":"2026-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"III\",market:\"US\",,,undefined,":[{"executeDate":"2021-06-03","recordDate":"2021-06-04","paymentDate":"2021-06-18","value":0.03,"currency":"USD"},{"executeDate":"2021-09-03","recordDate":"2021-09-07","paymentDate":"2021-09-24","value":0.03,"currency":"USD"},{"executeDate":"2021-12-02","recordDate":"2021-12-03","paymentDate":"2021-12-17","value":0.03,"currency":"USD"},{"executeDate":"2022-03-18","recordDate":"2022-03-21","paymentDate":"2022-04-06","value":0.03,"currency":"USD"},{"executeDate":"2022-06-02","recordDate":"2022-06-03","paymentDate":"2022-06-17","value":0.04,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"III\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":3,"updateTime":1679457600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/III\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"III","date":"2026-09-11","current":21.637983,"percent":0.61645,"low":-221.876594,"twenty":12.58915,"median":18.223516,"eighty":29.237367,"high":68.328883,"avg":0.809935,"sd":58.867544,"marketCap":245456252},"quantilePoints":[{"date":"2021-09-17","current":33.210859,"twenty":29.540957,"median":36.811685,"eighty":53.929654,"marketCap":366382200},{"date":"2021-09-24","current":32.859422,"twenty":29.540957,"median":36.811685,"eighty":53.929654,"marketCap":362505139},{"date":"2021-10-01","current":31.936898,"twenty":29.540957,"median":36.811685,"eighty":53.929654,"marketCap":352327856},{"date":"2021-10-08","current":33.386578,"twenty":29.603046,"median":36.811685,"eighty":53.929654,"marketCap":368320730},{"date":"2021-10-15","current":31.849038,"twenty":29.673426,"median":36.811685,"eighty":53.929654,"marketCap":351358591},{"date":"2021-10-22","current":33.386578,"twenty":29.768974,"median":36.811685,"eighty":53.929654,"marketCap":368320730},{"date":"2021-10-29","current":35.802712,"twenty":29.76934,"median":36.811685,"eighty":53.929654,"marketCap":394975520},{"date":"2021-11-05","current":32.443868,"twenty":29.838435,"median":36.811685,"eighty":53.929654,"marketCap":434715388},{"date":"2021-11-12","current":34.955794,"twenty":29.845286,"median":36.811685,"eighty":53.929654,"marketCap":468372678},{"date":"2021-11-19","current":34.77297,"twenty":29.845286,"median":36.811685,"eighty":53.929654,"marketCap":465923030},{"date":"2021-11-26","current":30.348649,"twenty":29.845286,"median":36.811685,"eighty":53.929654,"marketCap":406641551},{"date":"2021-12-03","current":28.886064,"twenty":29.82833,"median":36.811685,"eighty":53.929654,"marketCap":387044368},{"date":"2021-12-10","current":29.507663,"twenty":29.768974,"median":36.811685,"eighty":53.929654,"marketCap":395373171},{"date":"2021-12-17","current":26.984703,"twenty":29.661234,"median":36.811685,"eighty":53.929654,"marketCap":361568030},{"date":"2021-12-23","current":28.081642,"twenty":29.603046,"median":36.811685,"eighty":53.929654,"marketCap":376265917},{"date":"2021-12-31","current":27.862254,"twenty":29.504246,"median":36.811685,"eighty":53.929654,"marketCap":373326339},{"date":"2022-01-07","current":26.399668,"twenty":29.437039,"median":36.760945,"eighty":53.927618,"marketCap":353729156},{"date":"2022-01-14","current":25.302729,"twenty":29.255815,"median":36.760945,"eighty":53.927618,"marketCap":339031269},{"date":"2022-01-21","current":23.145416,"twenty":29.125104,"median":36.760945,"eighty":53.927618,"marketCap":310125424},{"date":"2022-01-28","current":22.670075,"twenty":29.042114,"median":36.760945,"eighty":53.927618,"marketCap":303756339},{"date":"2022-02-04","current":24.863954,"twenty":29.042114,"median":36.760945,"eighty":53.927618,"marketCap":333152114},{"date":"2022-02-11","current":25.887763,"twenty":29.042114,"median":36.760945,"eighty":53.927618,"marketCap":346870142},{"date":"2022-02-18","current":27.130961,"twenty":29.042114,"median":36.760945,"eighty":53.927618,"marketCap":363527748},{"date":"2022-02-25","current":26.107151,"twenty":29.042114,"median":36.760945,"eighty":53.927618,"marketCap":349809720},{"date":"2022-03-04","current":27.423478,"twenty":29.042114,"median":36.760945,"eighty":53.927618,"marketCap":367447185},{"date":"2022-03-11","current":22.999463,"twenty":29.042114,"median":36.760945,"eighty":53.927618,"marketCap":357158663},{"date":"2022-03-18","current":22.63323,"twenty":28.930434,"median":36.760945,"eighty":53.927618,"marketCap":351471428},{"date":"2022-03-25","current":21.138876,"twenty":28.720555,"median":36.760945,"eighty":53.927618,"marketCap":328265612},{"date":"2022-04-01","current":21.387935,"twenty":28.563876,"median":36.760945,"eighty":53.927618,"marketCap":332133248},{"date":"2022-04-08","current":20.640759,"twenty":28.47654,"median":36.760945,"eighty":53.927618,"marketCap":320530340},{"date":"2022-04-14","current":20.79642,"twenty":28.362763,"median":36.760945,"eighty":53.927618,"marketCap":322947612},{"date":"2022-04-22","current":19.769052,"twenty":28.214177,"median":36.760945,"eighty":53.927618,"marketCap":306993613},{"date":"2022-04-29","current":19.519993,"twenty":28.004454,"median":36.760945,"eighty":53.927618,"marketCap":303125977},{"date":"2022-05-06","current":18.430361,"twenty":27.931066,"median":36.760945,"eighty":53.927618,"marketCap":286205069},{"date":"2022-05-13","current":17.907825,"twenty":27.846885,"median":36.556933,"eighty":53.927618,"marketCap":305059795},{"date":"2022-05-20","current":17.625134,"twenty":27.555111,"median":36.381032,"eighty":53.927618,"marketCap":300244158},{"date":"2022-05-27","current":18.472496,"twenty":27.379781,"median":36.238493,"eighty":53.927618,"marketCap":314678973},{"date":"2022-06-03","current":18.274778,"twenty":27.167526,"median":36.092994,"eighty":53.927618,"marketCap":311310849},{"date":"2022-06-10","current":16.269354,"twenty":26.614253,"median":35.829538,"eighty":53.927618,"marketCap":277148453},{"date":"2022-06-17","current":16.551809,"twenty":26.372596,"median":35.640231,"eighty":53.822908,"marketCap":281960058},{"date":"2022-06-24","current":17.879343,"twenty":26.107151,"median":35.537925,"eighty":53.79462,"marketCap":304574602},{"date":"2022-07-01","current":19.093895,"twenty":25.975518,"median":35.458953,"eighty":53.271145,"marketCap":325264504},{"date":"2022-07-08","current":19.856521,"twenty":25.412423,"median":35.283172,"eighty":53.041064,"marketCap":338255838},{"date":"2022-07-15","current":19.291613,"twenty":24.849328,"median":35.178625,"eighty":52.906055,"marketCap":328632628},{"date":"2022-07-22","current":20.138975,"twenty":24.08147,"median":35.060591,"eighty":52.665026,"marketCap":343067443},{"date":"2022-07-29","current":21.071074,"twenty":23.209281,"median":34.955794,"eighty":52.523833,"marketCap":358945740},{"date":"2022-08-05","current":21.635982,"twenty":22.947966,"median":34.77297,"eighty":52.322009,"marketCap":368568950},{"date":"2022-08-12","current":16.409925,"twenty":22.628286,"median":34.72983,"eighty":52.322009,"marketCap":293507911},{"date":"2022-08-19","current":16.552576,"twenty":22.371718,"median":34.475053,"eighty":52.322009,"marketCap":296059374},{"date":"2022-08-26","current":16.15211,"twenty":21.544722,"median":34.282985,"eighty":52.322009,"marketCap":288896647},{"date":"2022-09-02","current":14.950714,"twenty":21.183009,"median":34.23369,"eighty":52.322009,"marketCap":267408467},{"date":"2022-09-09","current":14.817225,"twenty":21.074397,"median":34.193624,"eighty":52.322009,"marketCap":265020891},{"date":"2022-09-16","current":14.123085,"twenty":20.842582,"median":34.06831,"eighty":52.322009,"marketCap":252605498},{"date":"2022-09-23","current":12.948386,"twenty":20.628306,"median":33.98562,"eighty":52.322009,"marketCap":231594833},{"date":"2022-09-30","current":12.708107,"twenty":20.189817,"median":33.90293,"eighty":52.322009,"marketCap":227297197},{"date":"2022-10-07","current":12.761502,"twenty":19.975152,"median":33.869805,"eighty":52.322009,"marketCap":228252227},{"date":"2022-10-14","current":12.814898,"twenty":19.650749,"median":33.737549,"eighty":52.322009,"marketCap":229207257},{"date":"2022-10-21","current":13.268758,"twenty":19.370558,"median":33.630766,"eighty":52.322009,"marketCap":237325014},{"date":"2022-10-28","current":14.790528,"twenty":19.172983,"median":33.57217,"eighty":52.322009,"marketCap":264543376},{"date":"2022-11-04","current":11.924698,"twenty":18.940931,"median":33.57217,"eighty":52.322009,"marketCap":226819682},{"date":"2022-11-11","current":14.156908,"twenty":18.67839,"median":33.490051,"eighty":52.100253,"marketCap":269278547},{"date":"2022-11-18","current":14.055967,"twenty":18.383013,"median":33.406789,"eighty":51.591958,"marketCap":267358557},{"date":"2022-11-25","current":13.52603,"twenty":17.941577,"median":33.349337,"eighty":51.184669,"marketCap":257278611},{"date":"2022-12-02","current":13.223208,"twenty":17.811433,"median":33.272057,"eighty":50.857754,"marketCap":251518642},{"date":"2022-12-09","current":12.59233,"twenty":17.329516,"median":33.261363,"eighty":50.482919,"marketCap":239518707},{"date":"2022-12-16","current":11.406279,"twenty":16.879455,"median":33.138265,"eighty":50.207132,"marketCap":216958829},{"date":"2022-12-23","current":11.507219,"twenty":16.612253,"median":33.07907,"eighty":49.781169,"marketCap":218878818},{"date":"2022-12-30","current":11.60816,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":220798808},{"date":"2023-01-06","current":12.264273,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":233278741},{"date":"2023-01-13","current":13.122268,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":249598653},{"date":"2023-01-20","current":12.970857,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":246718668},{"date":"2023-01-27","current":13.122268,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":249598653},{"date":"2023-02-03","current":13.879322,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":263998575},{"date":"2023-02-10","current":13.879322,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":263998575},{"date":"2023-02-17","current":13.677441,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":260158596},{"date":"2023-02-24","current":12.945622,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":246238671},{"date":"2023-03-03","current":13.500795,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":256798614},{"date":"2023-03-10","current":12.166618,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":239998705},{"date":"2023-03-17","current":11.411218,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":225097683},{"date":"2023-03-24","current":12.147425,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":239620114},{"date":"2023-03-31","current":12.490989,"twenty":16.382886,"median":33.063229,"eighty":49.624683,"marketCap":246397249},{"date":"2023-04-06","current":12.294667,"twenty":16.382886,"median":33.063229,"eighty":49.624683,"marketCap":242524601},{"date":"2023-04-14","current":12.687311,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":250269897},{"date":"2023-04-21","current":12.270127,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":242040520},{"date":"2023-04-28","current":12.196506,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":240588276},{"date":"2023-05-05","current":12.245586,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":241556438},{"date":"2023-05-12","current":13.473902,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":246397249},{"date":"2023-05-19","current":14.20765,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":259815303},{"date":"2023-05-26","current":13.413927,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":245300481},{"date":"2023-06-02","current":13.387469,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":244816654},{"date":"2023-06-09","current":13.943076,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":254977029},{"date":"2023-06-16","current":14.075363,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":257396166},{"date":"2023-06-23","current":15.080746,"twenty":16.529212,"median":33.076029,"eighty":49.624683,"marketCap":275781606},{"date":"2023-06-30","current":14.154735,"twenty":16.551809,"median":33.076029,"eighty":49.624683,"marketCap":258847648},{"date":"2023-07-07","current":13.810789,"twenty":16.551809,"median":33.076029,"eighty":49.624683,"marketCap":252557892},{"date":"2023-07-14","current":14.260565,"twenty":16.551809,"median":33.076029,"eighty":49.624683,"marketCap":260782957},{"date":"2023-07-21","current":14.048906,"twenty":16.551809,"median":33.076029,"eighty":49.624683,"marketCap":256912338},{"date":"2023-07-28","current":13.387469,"twenty":16.551809,"median":33.076029,"eighty":49.624683,"marketCap":244816654},{"date":"2023-08-04","current":16.278939,"twenty":16.551809,"median":33.076029,"eighty":49.624683,"marketCap":254977029},{"date":"2023-08-11","current":16.275803,"twenty":16.382336,"median":32.997393,"eighty":49.558778,"marketCap":254927904},{"date":"2023-08-18","current":15.376759,"twenty":16.278939,"median":32.930248,"eighty":49.391703,"marketCap":240846172},{"date":"2023-08-25","current":15.40776,"twenty":16.232204,"median":32.835614,"eighty":49.042233,"marketCap":241331749},{"date":"2023-09-01","current":16.120795,"twenty":16.15211,"median":32.803437,"eighty":48.925743,"marketCap":252500019},{"date":"2023-09-08","current":15.035742,"twenty":16.031821,"median":32.75433,"eighty":48.809254,"marketCap":235504825},{"date":"2023-09-15","current":14.446713,"twenty":15.779779,"median":32.64723,"eighty":48.576274,"marketCap":226278863},{"date":"2023-09-22","current":13.733678,"twenty":15.562768,"median":32.609831,"eighty":48.459784,"marketCap":215110593},{"date":"2023-09-29","current":13.423662,"twenty":15.404575,"median":32.491023,"eighty":48.459784,"marketCap":210254823},{"date":"2023-10-06","current":13.950688,"twenty":15.345757,"median":32.431996,"eighty":48.459784,"marketCap":218509632},{"date":"2023-10-13","current":13.361659,"twenty":15.080746,"median":32.334816,"eighty":48.343294,"marketCap":209283669},{"date":"2023-10-20","current":13.051644,"twenty":14.911736,"median":32.178609,"eighty":48.324535,"marketCap":204427900},{"date":"2023-10-27","current":12.77263,"twenty":14.827387,"median":32.156546,"eighty":48.226804,"marketCap":200057707},{"date":"2023-11-03","current":15.032891,"twenty":14.614323,"median":32.100506,"eighty":48.180208,"marketCap":200057707},{"date":"2023-11-10","current":15.314305,"twenty":14.614323,"median":32.044484,"eighty":48.063719,"marketCap":203802770},{"date":"2023-11-17","current":15.975354,"twenty":14.614323,"median":32.022403,"eighty":47.932458,"marketCap":212600012},{"date":"2023-11-24","current":16.048804,"twenty":14.614323,"median":31.943078,"eighty":47.714249,"marketCap":213577483},{"date":"2023-12-01","current":15.27758,"twenty":14.614323,"median":31.841671,"eighty":47.187487,"marketCap":203314034},{"date":"2023-12-08","current":16.673128,"twenty":14.619662,"median":31.750721,"eighty":46.490677,"marketCap":221885989},{"date":"2023-12-15","current":16.673128,"twenty":14.619662,"median":31.53949,"eighty":46.22662,"marketCap":221885989},{"date":"2023-12-22","current":17.407627,"twenty":14.619662,"median":31.467912,"eighty":45.230776,"marketCap":231660702},{"date":"2023-12-29","current":17.554527,"twenty":14.614323,"median":31.234022,"eighty":45.040598,"marketCap":233615645},{"date":"2024-01-05","current":16.673128,"twenty":14.608983,"median":31.080268,"eighty":44.740412,"marketCap":221885989},{"date":"2024-01-12","current":16.452778,"twenty":14.608983,"median":30.97496,"eighty":44.593596,"marketCap":218953575},{"date":"2024-01-19","current":16.269154,"twenty":14.603644,"median":30.818124,"eighty":44.593596,"marketCap":216509897},{"date":"2024-01-26","current":17.554527,"twenty":14.608983,"median":30.62605,"eighty":44.463847,"marketCap":233615645},{"date":"2024-02-02","current":16.820028,"twenty":14.608983,"median":30.523385,"eighty":44.220503,"marketCap":223840932},{"date":"2024-02-09","current":16.122254,"twenty":14.608983,"median":30.418362,"eighty":43.923358,"marketCap":214554954},{"date":"2024-02-16","current":16.305879,"twenty":14.608983,"median":30.260593,"eighty":43.769861,"marketCap":216998633},{"date":"2024-02-23","current":15.608105,"twenty":14.608983,"median":30.141793,"eighty":42.75327,"marketCap":207712655},{"date":"2024-03-01","current":15.901904,"twenty":14.614323,"median":30.092043,"eighty":42.030433,"marketCap":211622540},{"date":"2024-03-08","current":34.784891,"twenty":14.614323,"median":29.930691,"eighty":41.395649,"marketCap":214066219},{"date":"2024-03-15","current":30.710223,"twenty":14.614323,"median":29.930691,"eighty":41.308941,"marketCap":188990710},{"date":"2024-03-22","current":32.281078,"twenty":14.614323,"median":30.092043,"eighty":41.308941,"marketCap":198657754},{"date":"2024-03-28","current":31.652736,"twenty":14.614323,"median":30.092043,"eighty":41.308941,"marketCap":194790936},{"date":"2024-04-05","current":31.966907,"twenty":14.608983,"median":30.092453,"eighty":41.339259,"marketCap":196724345},{"date":"2024-04-12","current":30.238966,"twenty":14.608983,"median":30.167144,"eighty":41.339259,"marketCap":186090597},{"date":"2024-04-19","current":28.589568,"twenty":14.608983,"median":30.167144,"eighty":41.339259,"marketCap":175940200},{"date":"2024-04-26","current":27.411426,"twenty":14.614323,"median":30.165826,"eighty":41.308941,"marketCap":168689917},{"date":"2024-05-03","current":26.39037,"twenty":14.614323,"median":30.165826,"eighty":41.308941,"marketCap":162406339},{"date":"2024-05-10","current":25.919114,"twenty":14.614323,"median":30.117759,"eighty":41.308941,"marketCap":159506226},{"date":"2024-05-17","current":-211.151442,"twenty":14.503289,"median":29.916131,"eighty":41.308941,"marketCap":153295947},{"date":"2024-05-24","current":-211.151442,"twenty":14.319403,"median":29.768426,"eighty":41.308941,"marketCap":153295947},{"date":"2024-05-31","current":-216.514018,"twenty":14.260565,"median":29.603046,"eighty":41.308941,"marketCap":157189177},{"date":"2024-06-07","current":-209.810798,"twenty":14.204967,"median":29.476834,"eighty":41.308941,"marketCap":152322639},{"date":"2024-06-14","current":-212.492085,"twenty":14.156908,"median":29.278446,"eighty":41.339259,"marketCap":154269254},{"date":"2024-06-21","current":-203.777899,"twenty":14.123085,"median":28.941526,"eighty":41.369578,"marketCap":147942755},{"date":"2024-06-28","current":-205.788865,"twenty":14.101821,"median":28.815898,"eighty":41.369578,"marketCap":149402716},{"date":"2024-07-05","current":-205.118543,"twenty":14.061456,"median":28.592041,"eighty":41.369578,"marketCap":148916062},{"date":"2024-07-12","current":-210.48112,"twenty":13.995991,"median":28.46557,"eighty":41.369578,"marketCap":152809293},{"date":"2024-07-15","current":-211.151442,"twenty":13.995991,"median":28.446337,"eighty":41.369578,"marketCap":153295947},{"date":"2024-08-02","current":-221.876594,"twenty":13.965764,"median":28.594514,"eighty":41.395649,"marketCap":161082407},{"date":"2024-08-09","current":-155.153276,"twenty":13.890161,"median":28.447288,"eighty":41.369578,"marketCap":158411495},{"date":"2024-08-16","current":-157.547617,"twenty":13.879322,"median":28.196854,"eighty":41.040322,"marketCap":160856117},{"date":"2024-08-23","current":-158.026486,"twenty":13.823503,"median":28.008512,"eighty":39.690077,"marketCap":161345042},{"date":"2024-08-30","current":-166.167244,"twenty":13.795681,"median":27.935383,"eighty":38.544,"marketCap":169656756},{"date":"2024-09-06","current":-154.195541,"twenty":13.753035,"median":27.569737,"eighty":38.347232,"marketCap":157433647},{"date":"2024-09-13","current":-151.322331,"twenty":13.704502,"median":27.313784,"eighty":38.122137,"marketCap":154500100},{"date":"2024-09-20","current":-156.111013,"twenty":13.672394,"median":27.130961,"eighty":37.980944,"marketCap":159389344},{"date":"2024-09-27","current":-154.195541,"twenty":13.62697,"median":26.595041,"eighty":37.894382,"marketCap":157433647},{"date":"2024-10-04","current":-155.153276,"twenty":13.599214,"median":26.468913,"eighty":37.779744,"marketCap":158411495},{"date":"2024-10-11","current":-150.364595,"twenty":13.553316,"median":26.233285,"eighty":37.589923,"marketCap":153522252},{"date":"2024-10-18","current":-152.280068,"twenty":13.524775,"median":26.107151,"eighty":37.433759,"marketCap":155477949},{"date":"2024-10-25","current":-147.012518,"twenty":13.48942,"median":25.919114,"eighty":37.27024,"marketCap":150099781},{"date":"2024-10-31","current":-150.364595,"twenty":13.450324,"median":25.485552,"eighty":37.015362,"marketCap":153522252},{"date":"2024-11-08","current":-52.964156,"twenty":13.423662,"median":24.845672,"eighty":36.750798,"marketCap":162811815},{"date":"2024-11-15","current":-53.318651,"twenty":13.387469,"median":24.004684,"eighty":36.556933,"marketCap":163901532},{"date":"2024-11-22","current":-53.238832,"twenty":13.341574,"median":23.198637,"eighty":36.327656,"marketCap":163656170},{"date":"2024-11-29","current":-58.905934,"twenty":13.314055,"median":22.981027,"eighty":36.238493,"marketCap":181076842},{"date":"2024-12-06","current":-58.267387,"twenty":13.27171,"median":22.651653,"eighty":35.999189,"marketCap":179113949},{"date":"2024-12-13","current":-58.427024,"twenty":13.239501,"median":22.455197,"eighty":35.783905,"marketCap":179604672},{"date":"2024-12-20","current":-55.074654,"twenty":13.19425,"median":21.621859,"eighty":35.607032,"marketCap":169299486},{"date":"2024-12-27","current":-53.957197,"twenty":13.130069,"median":21.342486,"eighty":35.505726,"marketCap":165864424},{"date":"2025-01-03","current":-51.88192,"twenty":13.070245,"median":21.138876,"eighty":35.459393,"marketCap":159485023},{"date":"2025-01-10","current":-49.96628,"twenty":13.021327,"median":20.901601,"eighty":35.211692,"marketCap":153596345},{"date":"2025-01-17","current":-51.88192,"twenty":12.972548,"median":20.664813,"eighty":35.117714,"marketCap":159485023},{"date":"2025-01-24","current":-51.562647,"twenty":12.952487,"median":20.578494,"eighty":35.032487,"marketCap":158503577},{"date":"2025-01-31","current":-49.168097,"twenty":12.915203,"median":20.138975,"eighty":34.93156,"marketCap":151142730},{"date":"2025-02-07","current":-51.083737,"twenty":12.802486,"median":19.831317,"eighty":34.780123,"marketCap":157031408},{"date":"2025-02-14","current":-51.40301,"twenty":12.725025,"median":19.519993,"eighty":34.72983,"marketCap":158012854},{"date":"2025-02-21","current":-49.48737,"twenty":12.667751,"median":19.333199,"eighty":34.575342,"marketCap":152124176},{"date":"2025-02-28","current":-49.00846,"twenty":12.601316,"median":19.122141,"eighty":34.324158,"marketCap":150652007},{"date":"2025-03-07","current":53.583718,"twenty":12.589786,"median":18.928478,"eighty":34.23369,"marketCap":152124176},{"date":"2025-03-14","current":56.52218,"twenty":12.589786,"median":18.928478,"eighty":34.23369,"marketCap":160466470},{"date":"2025-03-21","current":63.229713,"twenty":12.589786,"median":18.928478,"eighty":34.39907,"marketCap":179509154},{"date":"2025-03-28","current":64.079574,"twenty":12.589786,"median":18.928478,"eighty":34.546571,"marketCap":181921911},{"date":"2025-04-04","current":63.569657,"twenty":12.589786,"median":18.928478,"eighty":34.686729,"marketCap":180474257},{"date":"2025-04-11","current":60.17021,"twenty":12.590422,"median":18.990743,"eighty":34.733776,"marketCap":170823227},{"date":"2025-04-17","current":62.889768,"twenty":12.590422,"median":18.990743,"eighty":34.814432,"marketCap":178544051},{"date":"2025-04-25","current":62.379851,"twenty":12.589786,"median":18.928478,"eighty":34.943677,"marketCap":177096396},{"date":"2025-05-02","current":64.589491,"twenty":12.589786,"median":18.928478,"eighty":34.985212,"marketCap":183369566},{"date":"2025-05-09","current":25.015629,"twenty":12.589786,"median":18.928478,"eighty":35.046539,"marketCap":193020596},{"date":"2025-05-16","current":29.987043,"twenty":12.589786,"median":18.928478,"eighty":34.985212,"marketCap":231380025},{"date":"2025-05-23","current":29.29984,"twenty":12.589786,"median":18.928478,"eighty":34.985212,"marketCap":226077566},{"date":"2025-05-30","current":29.237367,"twenty":12.589786,"median":18.928478,"eighty":34.985212,"marketCap":225595524},{"date":"2025-06-06","current":29.424786,"twenty":12.589786,"median":18.928478,"eighty":34.964732,"marketCap":227041650},{"date":"2025-06-13","current":29.862097,"twenty":12.589786,"median":18.928478,"eighty":34.964732,"marketCap":230415942},{"date":"2025-06-20","current":29.612205,"twenty":12.58915,"median":18.866214,"eighty":34.964732,"marketCap":228487775},{"date":"2025-06-27","current":28.862529,"twenty":12.58915,"median":18.866214,"eighty":34.964732,"marketCap":222703274},{"date":"2025-07-03","current":31.923706,"twenty":12.58915,"median":18.866214,"eighty":34.955794,"marketCap":246323318},{"date":"2025-07-11","current":31.486395,"twenty":12.58915,"median":18.866214,"eighty":34.955794,"marketCap":242949026},{"date":"2025-07-18","current":29.237367,"twenty":12.58915,"median":18.866214,"eighty":34.89521,"marketCap":225595524},{"date":"2025-07-25","current":28.425218,"twenty":12.58915,"median":18.866214,"eighty":34.834126,"marketCap":219328982},{"date":"2025-08-01","current":26.925866,"twenty":12.58915,"median":18.866214,"eighty":34.784891,"marketCap":207759981},{"date":"2025-08-08","current":25.754678,"twenty":12.58915,"median":18.866214,"eighty":34.77297,"marketCap":202457522},{"date":"2025-08-15","current":30.470866,"twenty":12.58915,"median":18.866214,"eighty":34.704469,"marketCap":239531480},{"date":"2025-08-22","current":29.489913,"twenty":12.58915,"median":18.866214,"eighty":34.221243,"marketCap":231820205},{"date":"2025-08-29","current":31.39051,"twenty":12.58915,"median":18.866214,"eighty":34.114807,"marketCap":246760801},{"date":"2025-09-05","current":32.432773,"twenty":12.58915,"median":18.85295,"eighty":34.118522,"marketCap":254954031},{"date":"2025-09-12","current":32.126225,"twenty":12.58915,"median":18.866214,"eighty":34.114807,"marketCap":252544257},{"date":"2025-09-19","current":33.965513,"twenty":12.58915,"median":18.866214,"eighty":34.114807,"marketCap":267002898},{"date":"2025-09-26","current":35.314324,"twenty":12.58915,"median":18.866214,"eighty":34.309102,"marketCap":277605901},{"date":"2025-10-03","current":34.639918,"twenty":12.58915,"median":18.866214,"eighty":34.639918,"marketCap":272304399},{"date":"2025-10-10","current":33.842894,"twenty":12.58915,"median":18.866214,"eighty":34.704469,"marketCap":266038988},{"date":"2025-10-17","current":33.413727,"twenty":12.58915,"median":18.866214,"eighty":34.704469,"marketCap":262665306},{"date":"2025-10-24","current":34.088132,"twenty":12.58915,"median":18.866214,"eighty":34.704469,"marketCap":267966807},{"date":"2025-10-31","current":33.536346,"twenty":12.58915,"median":18.866214,"eighty":34.748399,"marketCap":263629215},{"date":"2025-11-07","current":28.380485,"twenty":12.58915,"median":18.866214,"eighty":34.701228,"marketCap":277248962},{"date":"2025-11-14","current":25.733601,"twenty":12.58915,"median":18.866214,"eighty":34.517299,"marketCap":251391546},{"date":"2025-11-21","current":24.557208,"twenty":12.58915,"median":18.866214,"eighty":34.309102,"marketCap":239899361},{"date":"2025-11-28","current":26.370814,"twenty":12.58915,"median":18.866214,"eighty":34.210751,"marketCap":257616479},{"date":"2025-12-05","current":28.282453,"twenty":12.58915,"median":18.866214,"eighty":33.965513,"marketCap":276291280},{"date":"2025-12-12","current":29.409829,"twenty":12.58915,"median":18.866214,"eighty":33.842894,"marketCap":287304624},{"date":"2025-12-19","current":29.26278,"twenty":12.58915,"median":18.866214,"eighty":33.529773,"marketCap":285868100},{"date":"2025-12-26","current":29.066715,"twenty":12.58915,"median":18.866214,"eighty":33.430508,"marketCap":283952736},{"date":"2026-01-02","current":28.331469,"twenty":12.58915,"median":18.866214,"eighty":33.342648,"marketCap":276770121},{"date":"2026-01-09","current":29.164747,"twenty":12.58915,"median":18.866214,"eighty":33.210859,"marketCap":284910418},{"date":"2026-01-16","current":29.80196,"twenty":12.58915,"median":18.866214,"eighty":33.054432,"marketCap":291135352},{"date":"2026-01-23","current":27.792289,"twenty":12.58915,"median":18.866214,"eighty":32.903351,"marketCap":271502869},{"date":"2026-01-30","current":27.400158,"twenty":12.58915,"median":18.866214,"eighty":32.739321,"marketCap":267672141},{"date":"2026-02-06","current":24.998355,"twenty":12.58915,"median":18.866214,"eighty":32.548436,"marketCap":244208930},{"date":"2026-02-13","current":22.35147,"twenty":12.58915,"median":18.866214,"eighty":32.359621,"marketCap":218351514},{"date":"2026-02-20","current":22.841634,"twenty":12.58915,"median":18.866214,"eighty":32.126225,"marketCap":223139924},{"date":"2026-02-27","current":23.429831,"twenty":12.58915,"median":18.866214,"eighty":32.068687,"marketCap":228886017},{"date":"2026-03-06","current":24.400849,"twenty":12.58915,"median":18.866214,"eighty":31.936898,"marketCap":227928335},{"date":"2026-03-13","current":20.466129,"twenty":12.58915,"median":18.866214,"eighty":31.809821,"marketCap":191174107},{"date":"2026-03-20","current":19.649525,"twenty":12.58915,"median":18.866214,"eighty":31.731279,"marketCap":183546212},{"date":"2026-03-27","current":19.7516,"twenty":12.58915,"median":18.866214,"eighty":31.635749,"marketCap":184499699},{"date":"2026-04-02","current":19.598487,"twenty":12.58915,"median":18.866214,"eighty":31.486395,"marketCap":183069469},{"date":"2026-04-10","current":20.415091,"twenty":12.58915,"median":18.866214,"eighty":31.417108,"marketCap":190697364},{"date":"2026-04-17","current":21.282732,"twenty":12.58915,"median":18.866214,"eighty":31.338565,"marketCap":198802001},{"date":"2026-04-24","current":20.466129,"twenty":12.58915,"median":18.866214,"eighty":31.102233,"marketCap":191174107},{"date":"2026-05-01","current":20.823393,"twenty":12.58915,"median":18.866214,"eighty":30.970444,"marketCap":194511311},{"date":"2026-05-08","current":18.809916,"twenty":12.58915,"median":18.839687,"eighty":30.838724,"marketCap":198802001},{"date":"2026-05-15","current":19.2371,"twenty":12.58915,"median":18.809916,"eighty":30.611773,"marketCap":203316914},{"date":"2026-05-22","current":19.780266,"twenty":12.58915,"median":18.739199,"eighty":30.409557,"marketCap":209057627},{"date":"2026-05-29","current":20.504486,"twenty":12.58915,"median":18.718829,"eighty":30.267569,"marketCap":216711911},{"date":"2026-06-05","current":19.644474,"twenty":12.58915,"median":18.739199,"eighty":30.174462,"marketCap":207622449},{"date":"2026-06-12","current":19.372892,"twenty":12.58915,"median":18.739199,"eighty":30.111989,"marketCap":204752092},{"date":"2026-06-18","current":18.829726,"twenty":12.58915,"median":18.698459,"eighty":29.987245,"marketCap":199011379},{"date":"2026-06-26","current":18.377089,"twenty":12.58915,"median":18.492688,"eighty":29.953208,"marketCap":194227452},{"date":"2026-07-02","current":18.965518,"twenty":12.58915,"median":18.492688,"eighty":29.862097,"marketCap":200446558},{"date":"2026-07-10","current":18.422353,"twenty":12.58915,"median":18.42051,"eighty":29.749013,"marketCap":194705845},{"date":"2026-07-17","current":18.558144,"twenty":12.58915,"median":18.377089,"eighty":29.67784,"marketCap":196141023},{"date":"2026-07-24","current":17.381286,"twenty":12.58915,"median":18.28067,"eighty":29.612205,"marketCap":183702812},{"date":"2026-07-31","current":18.648671,"twenty":12.58915,"median":18.223516,"eighty":29.51755,"marketCap":197097808},{"date":"2026-08-07","current":20.47213,"twenty":12.58915,"median":18.223516,"eighty":29.481004,"marketCap":239196370},{"date":"2026-08-14","current":21.422252,"twenty":12.58915,"median":18.223516,"eighty":29.444258,"marketCap":250297598},{"date":"2026-08-21","current":20.427796,"twenty":12.58915,"median":18.223516,"eighty":29.415812,"marketCap":238678367},{"date":"2026-08-28","current":20.883588,"twenty":12.58915,"median":18.223516,"eighty":29.304623,"marketCap":244003848},{"date":"2026-09-04","current":21.25651,"twenty":12.58915,"median":18.223516,"eighty":29.26278,"marketCap":248361060},{"date":"2026-09-11","current":21.007896,"twenty":12.58915,"median":18.223516,"eighty":29.237367,"marketCap":245456252}],"updateTime":1789359179447},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"III\",pageSize:20,pageCount:8,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2628227042","title":"藥捷安康-B(02617)：替恩戈替尼單藥治療晚期膽管癌患者確證性III期臨床完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2628227042","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628227042?lang=zh_tw&edition=fundamental","pubTime":"2026-04-17 18:41","pubTimestamp":1776422489,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B(02617)公布，公司核心产品替恩戈替尼(Tinengotinib, TT-00420)单药治疗晚期胆管癌患者的确证性III期临床研究，于近日完成首例患者给药。本试验为在中国开展的一项评价替恩戈替尼对比化疗用于既往经一线系统性治疗后复发或进展的、携带FGFR2融合╱重排或突变的、手术不可切除的晚期或转移性肝内胆管癌患者的疗效与安全性的随机对照、开放、多中心III期临床研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430049.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02617","III","BK1161","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627987288","title":"來凱LAE002乳腺癌III期臨床達到主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2627987288","media":"医药地理","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627987288?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 17:09","pubTimestamp":1776244140,"startTime":"0","endTime":"0","summary":"4月15日，来凯医药宣布，LAE002联合氟维司群，治疗HR+/HER2-乳腺癌III期临床试验取得强有力的积极顶线结果，成功达到其主要终点。临床结果显示，LAE002联合氟维司群组的中位无进展生存期为7.6个月，安慰剂联合氟维司群组为2.0个月，风险比为0.33。每日一次口服LAE002的患者耐受性良好，因不良事件停药比例极低；整体安全性特征与此前联合疗法评估数据一致。齐鲁制药获得在中国进行LAE002的研究、开发及商业化的独家许可。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-04-15/doc-inhuqnca3537414.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["III","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627407539","title":"中國生物製藥(01177)：維特柯妥拜單抗「CLDN18.2 ADC」一線胃及胃食管交界部腺癌III期臨床試驗完成首例患者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2627407539","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627407539?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 17:02","pubTimestamp":1776243779,"startTime":"0","endTime":"0","summary":"本研究为LM-302开展的第二项Ⅲ期临床试验，也是全球首个CLDN18.2 ADC药物采用无化疗方案用于胃癌一线治疗的Ⅲ期临床试验。这种“ADC+免疫”联合策略有望为CLDN18.2阳性胃癌患者带来更深度的肿瘤缓解。除本次启动的LM-302联合疗法用于一线治疗CLDN18.2阳性GC/GEJ的III期临床外，LM-302单药用于三线及以上CLDN18.2阳性GC/GEJ的III期临床研究已完成全部受试者入组。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428818.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YT58.USD","ADC","IE00BZ08YR35.GBP","BK4134","HK0000165453.HKD","BK1521","BK4231","01177","BK1515","BK4080","BK1589","IE00BZ08YS42.EUR","III","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627473918","title":"來凱醫藥-B(02105)：LAE 002(Afuresertib)III期臨床試驗(AFFIRM-205)達到無進展生存期(PFS)的主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2627473918","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627473918?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 08:22","pubTimestamp":1776212528,"startTime":"0","endTime":"0","summary":"II期临床试验是一项多中心、随机、双盲、安慰剂对照的关键性研究，旨在评估该联合疗法的抗肿瘤疗效及安全性。.每日一次口服LAE 002的治疗，患者耐受性良好，因不良事件而中止治疗的比例极低。本集团有权就许可区域内LAE 002的未来净销售额收取梯度销售分成，分成比率在十余个百分点至二十余个百分点。本集团计划在中国以外地区寻求战略合作伙伴，以加速LAE 002在国际市场的开发及商业化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","BK4211","02105","PFS","III","BK1161","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627427789","title":"軒竹生物-B(02575)：安奈拉唑鈉新適應症獲批開展III期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2627427789","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627427789?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 06:34","pubTimestamp":1776206064,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B 发布公告，本集团自主研发的创新药安奈拉唑钠肠溶片近日获得中国国家药品监督管理局药品审评中心批准，开展含安奈拉唑钠肠溶片的铋剂四联疗法根除幽门螺杆菌的III期临床研究。本次安奈拉唑钠新适应症III期临床试验申请获批，有助于拓展产品适应症范围，提升本公司在消化疾病治疗领域的影响力，对本公司长远发展及商业化布局具有重要意义。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428565.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02575","BK4134","III","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627498112","title":"港股異動 | 再鼎醫藥(09688)升逾3% 近日與安進達成全球臨床合作 Zoci正處於全球註冊性臨床III期階段","url":"https://stock-news.laohu8.com/highlight/detail?id=2627498112","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627498112?lang=zh_tw&edition=fundamental","pubTime":"2026-04-14 09:46","pubTimestamp":1776131184,"startTime":"0","endTime":"0","summary":"消息面上，近日，再鼎医药官微宣布，公司与安进公司达成一项全球临床研究合作，旨在评估再鼎医药处于临床阶段的靶向delta样配体3的抗体药物偶联物zocilurtatug pelitecan联合安进IMDELLTRA，一款靶向DLL3的双特异性T细胞衔接器疗法，用于治疗广泛期小细胞肺癌患者。作为该合作协议的一部分，安进将申办一项全球1b期研究，评估zoci联合IMDELLTRA在ES-SCLC患者中的安全性和有效性。再鼎医药将保留zoci的完整所有权，并将向安进提供临床研究用药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428082.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4531","IE0002141913.USD","LU2112291526.USD","BK1588","BK4585","BK4534","LU2488822045.USD","BK4134","LU0109394709.USD","LU0320765992.SGD","SG9999001440.SGD","BK4533","BK4526","LU2089984988.USD","LU0122379950.USD","LU2242652126.USD","LU2468319806.SGD","IE00B2B36J28.USD","III","ZLAB","LU1983299246.USD","IE0009355771.USD","BK4581","AMGN","LU0289739699.SGD","IE00BFTCPJ56.SGD","LU0868494617.USD","LU1061106388.HKD","LU2242646821.SGD","BK1161","BK4548","IE00BJJMRZ35.SGD","VXUS","09688","IE00BJT1NW94.SGD","BK4599","LU1023059063.AUD","BK4566","LU0889565916.HKD","LU1057294990.SGD","IE00B4R5TH58.HKD","BK4588","LU0058720904.USD","BK1574","BK4139","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627481537","title":"港股異動 | 科笛-B(02487)升逾3%  CU-20101（注射用A型肉毒毒素）完成中國III期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2627481537","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627481537?lang=zh_tw&edition=fundamental","pubTime":"2026-04-13 13:37","pubTimestamp":1776058657,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科笛-B(02487)涨超3%，截至发稿，涨3.25%，报4.76港元，成交额40.99万港元。消息面上，科笛今日宣布，集团完成CU-20101（注射用A型肉毒毒素）用于改善中度至重度眉间纹的中国III期临床试验。该临床试验旨在评估CU-20101单次及重复注射治疗中重度眉间纹的有效性和安全性。该临床试验以参比制剂保妥适®注射用A型肉毒毒素（“BOTOX®”）作为对照。该临床试验于2025年11月完成所有受试者出组，并于2026年1月完成数据库锁定且取得积极的顶线结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427621.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","VXUS","BK1161","BK4588","III","BK4134","02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627629100","title":"做好信息服務破解人崗錯配","url":"https://stock-news.laohu8.com/highlight/detail?id=2627629100","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627629100?lang=zh_tw&edition=fundamental","pubTime":"2026-04-13 09:10","pubTimestamp":1776042600,"startTime":"0","endTime":"0","summary":"解决这些问题，关键是建立一个统一、智能的就业信息服务平台。鼓励市场化人力资源服务机构参与公益性信息服务，给予税收优惠等支持。以精准信息服务打通毕业生就业“最后一公里”，让人才与岗位在透明、高效的信息环境中精准匹配，是以数字赋能提升人力资源配置效率的有益探索。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-04-13/doc-inhuihzn4873373.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["III","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627102514","title":"科笛-B(02487)：CU-20101(注射用A型肉毒毒素)用於改善中度至重度眉間紋完成中國III期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2627102514","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627102514?lang=zh_tw&edition=fundamental","pubTime":"2026-04-13 08:18","pubTimestamp":1776039501,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科笛-B 发布公告，本集团完成CU-20101用于改善中度至重度眉间纹的中国III期临床试验。在安全性方面，CU-20101的整体安全性良好，未发生导致提前煺出试验或导致死亡的不良事件，且未发生治疗有关的严重不良事件。CU-20101与BOTOX的安全性评估情况相近，未出现新的安全性信号。CU-20101多次重复注射给药后的有效性及安全性表现与单次用药相似。CU-20101将进一步丰富本集团的皮肤产品矩阵，并有利于与本集团现有产品形成协同效应。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427503.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","III","BK1161","02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626188654","title":"深桑達Ａ：公司研發重點圍繞數字與信息服務業務中的「雲數智」相關產品","url":"https://stock-news.laohu8.com/highlight/detail?id=2626188654","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626188654?lang=zh_tw&edition=fundamental","pubTime":"2026-04-09 17:33","pubTimestamp":1775727194,"startTime":"0","endTime":"0","summary":"证券之星消息，深桑达Ａ04月09日在投资者关系平台上答复投资者关心的问题。公司研发重点围绕数字与信息服务业务中的“云数智”相关产品、产业服务业务中的洁净室和智能运维等相关产品及工艺展开，具体情况请关注公司将披露的2025年年度报告。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260409/32134181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["III","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626975845","title":"開山股份(300257.SZ)肯尼亞Menengai III 35兆瓦地熱電站投入商業運營","url":"https://stock-news.laohu8.com/highlight/detail?id=2626975845","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626975845?lang=zh_tw&edition=fundamental","pubTime":"2026-04-09 07:54","pubTimestamp":1775692490,"startTime":"0","endTime":"0","summary":"智通财经APP讯，开山股份(300257.SZ)公告，公司下属公司Orpower Twenty Two Limited公司(简称“Orpower22”)顺利完成了肯尼亚Menengai III 35兆瓦地热电站的可靠性测试，该电站机组调试、测试工作已圆满结束。Menengai III 35兆瓦地热电站已于2026年3月10日正式投入商业运营。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426300.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0196","BK0117","BK4134","300257","III","BK0259","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105607138","title":"眾議院民主黨人要求緊急投票以阻止「第三次世界大戰」","url":"https://stock-news.laohu8.com/highlight/detail?id=1105607138","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105607138?lang=zh_tw&edition=fundamental","pubTime":"2026-04-08 02:02","pubTimestamp":1775584951,"startTime":"0","endTime":"0","summary":"众议院民主党高层呼吁议员立即返回华盛顿，就终止伊朗战争进行投票。由纽约州民主党领袖哈基姆·杰弗里斯及其他众议院民主党主要议员联合签署的声明指出，特朗普总统已“完全失控”，必须通过投票阻止其“将国家拖入第三次世界大战”。\n目前众议院休会至下周一。今年三月，一项反对伊朗战争的两党《战争权力决议案》曾以212票赞成、219票反对的结果在众议院被否决，当时议员投票结果基本按党派划线划分。\n（本文结束）道琼斯通讯社\n2026年4月7日 14:01 ET（18:01 GMT）\n版权所有（c）2026 道琼斯公司","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["III","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175143092","title":"美國對失蹤飛行員信息泄露事件展開調查","url":"https://stock-news.laohu8.com/highlight/detail?id=1175143092","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175143092?lang=zh_tw&edition=fundamental","pubTime":"2026-04-07 01:34","pubTimestamp":1775496862,"startTime":"0","endTime":"0","summary":"美国总统特朗普表示，当局已启动调查程序，追查有关失踪飞行员的信息如何被泄露给媒体。\"我们正在全力追查泄密者，\"他表态称。特朗普指责相关报道危及了在伊朗开展的救援行动。\n特朗普透露，计划要求首家报道救援行动的媒体公司公开其消息来源，但未具体点名涉事机构。\"要么交出线人，要么面临牢狱之灾，\"总统警告称，\"他们的行为不仅将那名飞行员置于险境，更连累了数百名参与搜救的人员。\"\n（本文源自道琼斯通讯社实时报道合集，完整内容可通过检索代码P/WSJL获取）\n（报道截止时间：2026年4月6日13:32美国东部时间/17:32格林威治时间）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4134","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624017509","title":"西藏自治區互聯網新聞信息服務單位許可信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2624017509","media":"中国西藏新闻网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624017509?lang=zh_tw&edition=fundamental","pubTime":"2026-04-02 20:35","pubTimestamp":1775133300,"startTime":"0","endTime":"0","summary":"截至2026年3月31日，经西藏自治区互联网信息办公室审批的互联网新闻信息服务单位总计86家，具体服务形式包括：互联网站19个、应用程序14个、公众账号440个，共计473个服务项。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-04-02/doc-inhtcnfv4278286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["160636","III","159792","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624123594","title":"百利天恒：iza-bren聯合用藥獲2個II/III期臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2624123594","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624123594?lang=zh_tw&edition=fundamental","pubTime":"2026-04-01 18:06","pubTimestamp":1775038011,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月1日，百利天恒(688506.SH)公告称，公司近日收到国家药监局签发的2个《药物临床试验批准通知书》，公司自主研发的创新生物药iza-bren(EGFR×HER3双抗ADC)的2个联合用药方案获得批准。获批适应症包括：联合阿比特龙±奥拉帕利、联合奥拉帕利用于去势抵抗性前列腺癌；联合贝伐珠单抗±化疗、联合奥拉帕利±贝伐珠单抗±化疗用于晚期卵巢癌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604013692048171.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604013692048171.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","688506","BK0239","III","02615","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624562436","title":"港股異動 | 歐康維視生物-B(01477)午後升逾16% OT-211治療乾眼症III期臨床試驗完成首例患者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2624562436","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624562436?lang=zh_tw&edition=fundamental","pubTime":"2026-04-01 14:26","pubTimestamp":1775024786,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，欧康维视生物-B午后涨超16%，截至发稿，涨15.33%，报8.5港元，成交额2606.87万港元。消息面上，欧康维视生物发布公告称，OT-211在中国开展的III期临床试验已完成首例患者入组。首例患者成功入组标志着OT-211在中国的临床开发取得重要里程碑进展，并体现了集团致力于为DED患者推进创新疗法。公开资料显示，Alcon Inc.开发出AR-15512的0.003%浓度滴眼液配方，并完成一项IIb期及三项III期临床试验。OT-211已于2025年5月28日获FDA批准用于治疗DED的体征及症状。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423857.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1191","III","BK4134","BK4585","01477","VXUS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623583940","title":"康寧傑瑞製藥-B(09966)：KN026新輔助治療HER2陽性乳腺癌III期臨床研究達到主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2623583940","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623583940?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 19:03","pubTimestamp":1774955020,"startTime":"0","endTime":"0","summary":"BC是中国女性发病率最高的恶性肿瘤，其中HER2阳性亚型约占20%至30%。该研究旨在比较KN026联合HB1801±卡铂对比曲妥珠单抗联合帕妥珠单抗和多西他赛±卡铂新辅助治疗早期和局部晚期HER2阳性BC的有效性及安全性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423118.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","III","BK1161","BK4134","09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623347904","title":"宜明昂科-B(01541)：IMM0306治療複發性╱難治性濾泡性淋巴瘤的III期臨床試驗完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2623347904","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623347904?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 00:28","pubTimestamp":1774888085,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B 发布公告，IMM0306联合来那度胺治疗复发性╱难治性滤泡性淋巴瘤的III期临床试验顺利完成首例患者给药。由本集团独立研发的IMM0306是一种靶向分化簇47 及分化簇20 的双特异性分子，是全球首个进入临床阶段的CD47和CD20双靶向双特异性分子。截至本公告日期，本集团拥有IMM0306的全球知识产权及商业化权利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422402.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","01541","BK4134","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623346987","title":"歐康維視生物-B(01477)：OT-211 III期臨床試驗完成首例患者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2623346987","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623346987?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 22:05","pubTimestamp":1774879506,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧康维视生物-B 发布公告，OT-211 在中国开展的III期临床试验已完成首例患者入组。OT-211 为一种 0.003%浓度滴眼液配方，亦为首款获美国食品药品监督管理局批准用于治疗干眼症的TRPM8激动剂。首例患者成功入组标志着OT-211在中国的临床开发取得重要里程碑进展，并体现了集团致力于为DED患者推进创新疗法。OT-211 已于2025年5月 28日获FDA批准用于治疗DED的体征及症状。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422176.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1574","BK4134","BK1191","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622830947","title":"益方生物(688382.SH)：D-2570治療銀屑病註冊性III期臨床試驗完成全部受試者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2622830947","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622830947?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 16:48","pubTimestamp":1774514885,"startTime":"0","endTime":"0","summary":"智通财经APP讯，益方生物(688382.SH)公告，公司自主研发的TYK2抑制剂D-2570用于治疗中重度斑块状银屑病(PsO)的注册性III期临床试验已于近日完成全部受试者入组。公告显示，D-2570是公司自主研发的一款靶向酪氨酸激酶2(TYK2)的新型口服选择性抑制剂，用于治疗银屑病等自身免疫性疾病。D-2570通过选择性结合TYK2假激酶域JH2部位，抑制TYK2激酶的活性，进而阻断TYK2依赖性的细胞因子信号传导介导的STAT蛋白的磷酸化，抑制炎症因子释放，参与免疫调节。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","688382","BK4134","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":8,"totalSize":176,"code":"91000000","status":"200"}]}}